Product Description
Benralizumab is a monoclonal antibody that binds to the human interleukin-5 (IL-5) receptor (IL-5R), thereby preventing IL-5 from binding to its receptor and inhibiting differentiation and maturation of eosinophils in the bone marrow. (Sourced from: https://doi.org/10.1186/s12890-020-01220-9)
Mechanisms of Action: IL5 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Mexico, Netherlands, New Zealand, Philippines, Poland, Russia, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location, Vietnam
Active Clinical Trial Count: 44
Highest Development Phases
Phase 3: Asthma|Bronchiectasis|Chronic Obstructive Pulmonary Disease|Churg-Strauss Syndrome|Cystic Fibrosis|Eosinophilia|Eosinophilic Esophagitis|Eosinophilic Granuloma|Gastritis|Gastroenteritis|Granulomatosis with Polyangiitis|Hypereosinophilic Syndrome|Inflammation|Nasal Polyposis|Pemphigoid, Bullous|Pulmonary Eosinophilia|Sinusitis|Vasculitis
Phase 2: Chronic Spontaneous Urticaria|Dermatitis, Atopic|Drug Hypersensitivity|Prurigo|Pruritus
Phase 1: COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| D3250C00024 | P3 |
Unknown Status |
Asthma|Inflammation |
2032-09-30 |
|
| DOMINICA | P3 |
Recruiting |
Pulmonary Eosinophilia|Asthma |
2030-05-05 |
|
| BENRADRESS | P2 |
Not yet recruiting |
Drug Hypersensitivity |
2029-01-05 |
|
| BRISOTE | P3 |
Not yet recruiting |
Asthma|Pulmonary Eosinophilia |
2027-10-29 |